Workflow
Kirby McInerney LLP Urges Investors in Actinium Pharmaceuticals, Inc. (ATNM) to Inquire About Their Rights in Class Action Lawsuit
Actinium PharmaceuticalsActinium Pharmaceuticals(US:ATNM) GlobeNewswire News Roomยท2025-05-06 00:00

Core Viewpoint - A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for misleading investors regarding the approval prospects of its Biologics License Application for lomab-B, leading to significant stock price decline [1][4]. Group 1: Lawsuit Details - The class action lawsuit is filed in the U.S. District Court for the Southern District of New York on behalf of investors who acquired Actinium securities from October 31, 2022, to August 2, 2024 [1]. - Investors have until May 27, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Regulatory Update - On August 5, 2024, Actinium announced that the FDA determined the data from its Sierra trial did not support a BLA filing for lomab-B, necessitating an additional clinical study [3]. - Following this announcement, Actinium's share price fell by $3.69, or approximately 59%, from $6.17 on August 2, 2024, to $2.48 on August 5, 2025 [3]. Group 3: Allegations - The complaint alleges that during the Class Period, Actinium misled the market into believing that the data submitted for its BLA would meet FDA guidelines for acceptance and approval [4].